Prostate Cancer

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. February 18, 2025

Treatment switching between Enzalutamide and Abiraterone Acetate and time to oral opioid initiation in castration-resistant prostate cancer patients. February 18, 2025

The lived experience of active surveillance for prostate cancer: a systematic review and meta-synthesis. February 18, 2025

Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer. February 18, 2025

Mainstreaming improved adoption of germline testing for Veterans Affairs patients with metastatic prostate cancer without exacerbating disparities. February 18, 2025

PSA Density to Select MRI Targeted versus Combined Biopsy for Prostate Cancer Diagnosis: A Secondary Analysis of the Trio Study. February 17, 2025

A multicentre implementation trial of an Artificial Intelligence-driven biomarker to inform Shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: the ASTuTE protocol. February 17, 2025

An Analysis of Print and Online Media's Representation of Prostate Cancer in Public Figure. February 17, 2025

Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer. February 17, 2025

Prostate Cancer Mortality in Men Aged 70 Years Who Recently Underwent Prostate-Specific Antigen Screening. February 17, 2025

Clinical and Imaging Predictors of False-Positive and False-Negative Results in Prostate Multiparametric MRI Using PI-RADS Version 2. February 17, 2025

Association Between Medicaid Expansion and Insurance Status, Risk Group, Receipt, and Refusal of Treatment Among Men with Prostate Cancer. February 14, 2025

Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer. February 14, 2025

Patient-Reported Outcome Measures and Decision Regret After Salvage Radical Prostatectomy for Recurrent Prostate Cancer Following Radiotherapy or Focal Therapy. February 14, 2025

Couple-based lifestyle intervention for minority prostate cancer survivors: a randomized feasibility trial. February 14, 2025

The Germline and Somatic Origins of Prostate Cancer Heterogeneity. February 14, 2025

Do trial benefits predict real-world gains in metastatic castration resistant prostate cancer. February 14, 2025

Biochemical response to neoadjuvant hormonal therapy predicts long-term prostate cancer survival outcomes after high-dose-rate brachytherapy with external beam radiotherapy. February 13, 2025

Protocol for a randomised phase 3 trial evaluating the role of Finasteride in Active Surveillance for men with low and intermediate-risk prostate cancer: the FINESSE Study. February 13, 2025

The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer. February 13, 2025

Page 1 of 1459